BioSpace News Archive

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark.

Protillion Biosciences today announced the completion of an $18 million Series A financing from ARCH Venture Partners and Illumina Ventures.

Lipocine Inc. today announced that it has completed enrollment in its Phase 2 proof-of-concept (“POC”) study evaluating the therapeutic potential of LPCN 1148 for the management of decompensated cirrhosis of various etiologies. Lipocine intends to explore partnering LPCN 1148.

DarioHealth Corp. (NASDAQ: DRIO) (the “Company”), a leader in the global digital therapeutics (DTx) market, announced the publication of a new study in the peer-reviewed journal Frontiers in Physiology today demonstrating the effectiveness of the Company’s musculoskeletal solution, which uses real-time biofeedback and behavior training to reduce back pain.

Ordaōs today announced a joint development agreement to create new therapeutics for two novel targets in Acute Myeloid Leukemia (AML) with Yatiri Bio, a biotechnology company that has developed a proprietary platform that links patient proteomic and clinical data to context-specific ex-vivo model systems to drive efficient drug development and advance personalized medicines.

BioLife Solutions, Inc. (NASDAQ: BLFS) today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on January 9, 2023, in advance of management’s meetings with investors, customers, and partners concurrent with the 41st Annual J.P. Morgan Health Care Conference in San Francisco January 9-12.

UroGen Pharma Ltd. announced that the Phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for intravesical solution in development for the treatment of LG-IR-NMIBC is fully enrolled.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase 1 study.

Ensysce Biosciences, Inc. today announced data demonstrating the overdose protection of its drug product, PF614-MPAR from the clinical study being conducted in Healthy Subjects by Dr. Maria Bermudez MD, at Quotient Sciences, Miami, Florida.

Albireo Pharma, Inc. (Nasdaq: ALBO) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation application to the European Medicines Agency (EMA) seeking approval for a second Bylvay indication for use in patients with Alagille syndrome (ALGS) in the second half of 2023.